Ознакомительная версия. Доступно 28 страниц из 137
Phillips C. B. Medicine goes to school: Teachers as sickness brokers for ADHD // PLoS Medicine. 2006. Vol. 3. № 4, e182.
Healy D. The latest mania: Selling bipolar disorder // PLoS Medicine. 2006. Vol. 3. № 5, e236.
Scott S. The medicalisation of shyness: from social misfits to social fitness // Sociology of Health & Illness. 2006. Vol. 28. № 2. P. 133–153.
Wolinsky H. Disease mongering and drug marketing // EMBO reports 2005. Vol. 6. № 7. P. 612–614.
Woloshin S., Schwartz L. M. Giving legs to restless legs: A case study of How the media helps make people sick // PLoS Medicine. 2006. Vol. 3. № 4, e170.
Gagnon M.-A., Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States // PLoS Medicine. 2008. Vol. 5. № 1, e1.
Branding the cure: a consumer perspective on corporate social responsibility, drug promotion and the pharmaceutical industry in Europe. London: Consumers International, 2006.
Matheson A. The disposable author: how pharmaceutical marketing is embraced within medicine’s scholarly literature // Hastings Center Report. 2016. July/August. Vol. 46. № 4. P. 31–37.
Giannakakis I. A., Ioannidis J. P. A. Arabian nights – 1001 tales of how pharmaceutical companies cater to the material needs of doctors: case report // BMJ. 2000. December 23. Vol. 321. № 7276. P. 1563–1564.
Donohue J. M., Cevasco M., Rosenthal M. B. A decade of direct-to-consumer advertising of prescription drugs // The New England journal of medicine. 2007. Vol. 357. № 7. P. 673–681.
Applbaum K. Is marketing the enemy of pharmaceutical innovation? // Hastings Center Report. 2009. July-August. Vol. 39. № 4. P. 13–17.
Ioannidis J. P. A. Mega-trials for blockbusters // JAMA. 2013. January 16. Vol. 309. № 3. P. 239–240.
Moffatt B., Elliott C. Ghost marketing: pharmaceutical companies and ghostwritten journal articles // Perspectives in Biology and Medicine. 2007.·February. Vol. 50. № 1. P. 18–31.
Goldbloom D. S. Physicians and the pharmaceutical industry // CPA Bulletin de l’APC. 2003. October. P. 3–4.
Goldbloom D. S. Les médecins et l’industrie pharmaceutique // CPA Bulletin de l’APC. 2003. October. P. 4–5.
Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift? // JAMA. 2000. Vol. 283. № 3. P. 373–380.
Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch // Chest. 1992. Vol. 102. № 270–273.
Grande D., Frosch D. L., Perkins A. W., Kahn B. E. Effect of exposure to small pharmaceutical promotional items on treatment preferences // Archives of Internal Medicine. 2009. Vol. 169. № 9. P. 887–893.
Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a systematic review // BMJ Quality & Safety. 2005. Vol. 14. P. 246–250.
Frosch D. L., Krueger P. M., Hornik R. C., Cronholm P. F., Barg F. K. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising // Annals of family medicine. 2007. January-February. Vol. 5. № 1. P. 6–13.
Ventola C. L. Direct-to-consumer pharmaceutical advertising. Therapeutic or Toxic? // P & T: a peer-reviewed journal for formulary management. 2011. October. Vol. 36. № 10. P. 669–684.
Frosch D. L., Grande D., Tarn D. M., Kravitz R. L. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising // American journal of public health. 2010. January. Vol. 100. № 1. P. 24–32.
Experimental evaluation of the impact of distraction on consumer understanding of risk and benefit information in direct-to-consumer prescription drug television advertisements. 2011. June.
Grimes T. Mild auditory-visual dissonance in television news may exceed viewer attentional capacity // Human Communication Research. 1991. December 1. Vol. 18. № 2. P. 268–298.
Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R. et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial // JAMA. 2005. April 27. Vol. 293. № 16. P. 1995–2002.
Mintzes B., Barer M. L., Kravitz R. L., Kazanjian A., Bassett K., Lexchin J. et al. Influence of direct to consumer pharmaceutical advertising and patients’ requests on prescribing decisions: two site cross sectional survey // British Medical Journal. 2002. Vol. 324. № 7332. P. 278–279.
Hochhauser M. Is this a seeding trial? // Journal of Clinical Research Best Practices. 2009. June. Vol. 5. № 6.
Vedula S. S., Bero L., Scherer R. W., Dickersin K. Outcome reporting in industry-sponsored trials of gabapentin for off-label use // The New England Journal of Medicine. 2009. № 20. Vol. 361. P. 1963–1971.
Sox H. C., Rennie D. Seeding trials: just say “No” // Annals of Internal Medicine (Editorial). 2008. August 19. Vol. 149. № 4. P. 279–280.
Kuriya B., Schneid E. C., Bell C. M. Quality of pharmaceutical industry press releases based on original research // PLoS ONE. 2008. Vol. 3. № 7, e2828.
Woloshin S., Schwartz L. M. Press releases: translating research into news // JAMA. 2002. Vol. 287. № 21. P. 2856–2858.
Yavchitz A., Boutron I., Bafeta A., Marroun I., Charles P., Mantz J. et al. Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study // PLoS Med. 2012. Vol. 9. № 9, e1001308.
Welch H. G., Black W. C. Overdiagnosis in Cancer // Journal of the National Cancer Institute. 2010. May 5. Vol. 102. № 9. P. 605–613.
Барчук А., Талантов П. Война на опережение. Скрининг не станет очередной панацеей от рака, нужно менять привычки людей // Новая газета. 2018. 17 сентября. № 102.
Marmot M. G., Altman D. G., Cameron D. A., Dewar J. A., Thompson S. G., Wilcox M. The benefits and harms of breast cancer screening: an independent review // British Journal of Cancer. 2013. June 11. Vol. 108. № 11. P. 2205–2240.
Gøtzsche P. C., Nielsen M. Screening for breast cancer with mammography (Review). Cochrane Database of Systematic Reviews. 2011. № 4.
Yaffe M. J., Mainprize J. G. Risk of radiation-induced breast cancer from mammographic screening // Radiology. 2011. January. Vol. 258. № 1. P. 98–105.
WHO position paper on mammography screening. World Health Organization, 2014.
Schroder F. H., Hugosson J., Roobol M. J. et al. Screening and prostate-cancer mortality in a randomized european study // The New England Journal of Medicine. 2009. Vol. 360. № 13. P. 1320–1328.
Ознакомительная версия. Доступно 28 страниц из 137
